Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5713-5715 in Birch Pollen Allergy
NCT06602739Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of REGN5713, atisnolerbart in allergic conjunctivitis (AC), sponsored by Regeneron Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
REGN5713atisnolerbart
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT06602739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602739.